Erica Zhang* and Sarah Azim
Haematological cancers are treated with haematopoietic stem cell transplantation. With treatment efficacy improving, extensive long-term follow-up by competent professionals in a multidisciplinary context has become critical. This article discusses the gynaecological consequences of haematopoietic stem cell transplantation, including pre-treatment counselling, the onset of menopausal symptoms, bone loss, graft-versus-host disease, and secondary genital cancers. Wherever possible, the information around the occurrence, symptoms, and management of these problems is summarised using current clinical guidelines. Although there are few highlevel data on this patient population, observational data and data from other immunocompromised populations are discussed.
Published Date: 2022-05-31; Received Date: 2022-05-05
